Improving kidney transplant outcomes in teens and young adults
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 13 and 20 years old.
- This will be your first kidney transplant.
- You have had Epstein-Barr virus (EBV) in the past, confirmed by a blood test.
- You do not have active infections, cancer, or certain kidney diseases that can come back after transplant.
- You are up to date on vaccines (unless a doctor says it's not safe for you).
- You agree to use birth control if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an experimental drug can prevent a common virus (EBV) from causing problems in people who receive a kidney from an EBV-positive donor but have never been exposed to EBV themselves. It aims to reduce the risk of transplant-related complications.
This trial tests a blood test that may help monitor kidney transplant health by detecting signs of rejection earlier. It aims to see if using this blood test can lead to better long-term outcomes for transplant recipients.
This study tests a new medicine called TNX-1500 that may help prevent the body from rejecting a new kidney. It is for people who are already waiting for a kidney transplant and aims to make the transplant more successful.
This trial tests if a special stem cell treatment (using your own stem cells) can reset your immune system so you can accept a kidney from a deceased donor, even if you have very high antibody levels that make it hard to find a match. It's for people who have been waiting a long time and haven't had a transplant offer.
This Phase 3 study tests whether switching teens from one anti-rejection medicine to belatacept works as well as staying on the current regimen. It also looks at safety and whether patients can stay on their anti-rejection medicines.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.